Michael J. Pishvaian

Also affiliated with Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 18 papers. Top paper: “Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study”.

Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study

Cancer(2020)10.1002/cncr.32883

N/A

4.9DataRank · unranked

150 citations

Emily Bergsland, Bert H. O’Neil, Armando Santoro, Jan H.M. Schellens, Roger B. Cohen +15 more

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005147

N/A

1.7DataRank · unranked

66 citations

Michael J. Pishvaian, Margaret K. Callahan, Amy Weise, Branimir I. Šikić, Osama E. Rahma +19 more

Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma

Neoplasia(2025)10.1016/j.neo.2025.101152

N/A

0.222DataRank · unranked

3 citations

Eleanor Jenkins, Rutuj P. Kusurkar, Sherry Lee, Wei Jiang, Avinoam Nevler +7 more

Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice

Gastroenterology(2020)10.1053/j.gastro.2020.11.044

N/A

0DataRank · unranked

92 citations

Sivanesan Dakshanamurthy, Matthew McCoy, Anastasia Mavropoulos, Bedilu Allo, Aimy Sebastian +14 more

A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1301

N/A

0DataRank · unranked

47 citations

Hongkun Wang, Aiwu Ruth He, Jimmy J. Hwang, Brandon G. Smaglo, Sunnie S. Kim +5 more

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1789

N/A

0DataRank · unranked

53 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-20-0652

N/A

0DataRank · unranked

36 citations

Grace A. McCarthy, Teena Nerwal, Avinoam Nevler, James B. DuHadaway, Matthew McCoy +23 more

Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) mutations: SWOG S2001.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps447

N/A

0DataRank · unranked

13 citations

Katherine A. Guthrie, Michael J. Pishvaian, Andrew M. Lowy, E. Gabriela Chiorean, Mai T. Duong +3 more

Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix

Journal of Clinical Investigation(2020)10.1172/jci136760

N/A

0DataRank · unranked

136 citations

Robert J. Torphy, Katja Steiger, Henry Hongo, Alexa J. Ritchie, Mark Kriegsmann +18 more

APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation—ECOG-ACRIN EA2192.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps763

N/A

0DataRank · unranked

8 citations

Sung Chul Hong, Anup Kasi, Eileen M. O’Reilly, Shishir K. Maithel, Xin Yao +10 more

Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4198

N/A

0DataRank · unranked

6 citations

Katherine A. Guthrie, Michael J. Pishvaian, Kim Anna Reiss, Andrew M. Lowy, Davendra Sohal +7 more

Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4202

N/A

0DataRank · unranked

3 citations

Sung Chul Hong, Anup Kasi, Eileen M. O’Reilly, Shishir K. Maithel, Xin Yao +10 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176.v1

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0002

N/A

0DataRank · unranked

11 citations

Won Jin Ho, Daniel Shu, Jennifer N. Durham, Madelena Brancati, Heather Davis Bruning +23 more

Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database

The Oncologist(2025)10.1093/oncolo/oyaf007

N/A

0DataRank · unranked

7 citations

Edik M. Blais, John Davelaar, Matthew Ebia, Angela Minasyan, Nima Nikravesh +13 more

Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics

Seminars in Radiation Oncology(2025)10.1016/j.semradonc.2025.08.004

N/A

0DataRank · unranked

2 citations

Michael J. Pishvaian, Maria Farooq

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30074-7

N/A

0DataRank · unranked

546 citations

Edik M. Blais, Jonathan R. Brody, Emily E. Lyons, Patricia DeArbeloa, Andrew Hendifar +11 more